<DOC>
	<DOCNO>NCT01858649</DOCNO>
	<brief_summary>The study design analyze pathological tumor response resect colorectal cancer metastasis preoperative treatment bevacizumab combine FOLFOX FOLFIRI regimen prospective cohort correlate response patient 's outcome .</brief_summary>
	<brief_title>Study Comparing Pathological Responses Observed Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX FOLFIRI .</brief_title>
	<detailed_description>This phase II , openlabel , randomize study patient confirm diagnosis resectable metastatic colorectal adenocarcinoma , receive prior chemotherapy metastatic disease . The study design compare pathological response observe pre-operative chemotherapy bevacizumab FOLFOX FOLFIRI .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Female male patient least 18 year time inform consent sign 2.ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 3.Histological cytological confirm diagnostic adenocarcinoma colon rectum , without primary tumour situ . Wildtype mutate KRAS tumor status . 4.Patients must present resectable metastatic disease decision preoperative chemotherapy consider . Resectability could plan one multiple stage indicate . As commonly admit , resectability mean surgical clearance ( +/ radiofrequency ablation ) detectable ( liver ) lesion tumorfree margin compatible adequate hepatic reserve . Practically , bilateral tumor location , number location lesion , inadequate hepatic reserve remain main decisional factor . 5.Partial minor resection metastatic disease allow within 3 month inclusion patient never receive chemotherapy mCRC . 6.Extra hepatic metastatic location limit 1 site . Extrahepatic location must easily resectable one stage surgery . 7.Patients may receive adjuvant chemotherapy ( neo ) adjuvant chemoradiotherapy pelvis , provide last dose chemotherapy administer least 6 month prior inclusion ( 12 month oxaliplatin ) . Previous radiotherapy pelvis exclusion criterion . 8.Adequate haematological , renal hepatic function follow : Haematological Neutrophils &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L Renal Creatinine &lt; 1.5 x ULN ( Upper Limit Normal ) Hepatic Bilirubin &lt; 1.5 X ULN AST ( Aspartate aminotransferase ) , ALT ( Alanine Aminotransferase ) &lt; 5 x ULN Phos Alc . &lt; 5 x ULN 9.Proteinuria &lt; 2+ ( dipstick urinalysis ) =1g/24hour . 10.No history myocardial infarction and/or stroke within 6 month prior randomization . No uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) , history hypertensive crisis , hypertensive encephalopathy . 11.Female patient must either postmenopausal , sterile ( surgically radiation chemicallyinduced ) , sexually active use acceptable method contraception . 12.Male patient must surgically sterile sexually active premenopausal partner must use acceptable method contraception . 13.Life expectancy least 3 month without active treatment . 1.Non resectable mCRC ( metastatic ColoRectal Cancer ) ( resectability remain uncertain unprobable 3 month chemotherapy , patient exclude trial ) . 2.Prior chemotherapy systemic therapy mCRC . Adjuvant chemotherapy colorectal cancer exclusion criterion provide complete 6 month prior inclusion . Oxaliplatinbased chemotherapy must complete 1 year prior inclusion . 3.Prior utilization bevacizumab , aflibercept ( antiVEGF ( vascular endothelial growth factor ) therapy ) . 4.Previous radiotherapy deliver upper abdomen . 5.Evidence ascites , cirrhosis , portal hypertension , main portal venous tumour involvement thrombosis determine clinical radiologic assessment . 6.Prior major liver resection : remnant liver &lt; 50 % initial liver volume . 7.Nonmalignant disease would render patient unsuitable treatment accord protocol . 8.Concurrent central nervous system metastases 9.Peripheric neuropathy â‰¥ grade 2 . 10.Interstitial lung disease 11.Pregnant breast feeding . 12.The patient previous concomitant malignancy , except : Invasive malignancy remission 5 year non melanoma skin cancer carcinoma situ cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>liver</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Pathological response</keyword>
</DOC>